Advaxis has assembled a world class management team with extensive expertise and a successful track record in drug development and commercialization of cancer immunotherapies.
Daniel J. O’Connor, J.D.
President, Chief Executive Officer and Director
Daniel O’Connor is President, Chief Executive Officer and Director of Advaxis. As CEO, Mr. O’Connor has led the transformation of Advaxis into a leading cancer immunotherapy company with collaboration partners including major biopharmaceutical manufacturers like Amgen Inc., Merck & Co. and MedImmune. . In 2017, Mr. O’Connor was appointed Vice Chairman of BioNJ, leveraging his experience to guide and support the organization’s mission of fostering the innovation of research-based life science companies in the New Jersey region.
Mr. O’Connor has 20 years of executive, legal, and regulatory experience in the biopharmaceutical industry, including executive leadership positions at ImClone Systems and PharmaNet, now known as inVentiv Health. At ImClone, Mr. O’Connor served as senior vice president, general counsel, and corporate secretary where he supported the clinical development, launch, and commercialization of ERBITUX® and resolved several critical corporate issues, including extensive licensing negotiations in advance of ImClone’s sale to Eli Lilly in 2008. As General Counsel at PharmaNet, Mr. O’Connor was part of the senior leadership team that grew the company from a start-up contract research organization to a world leader in clinical research.
Previously, Mr. O’Connor, a licensed attorney in New Jersey and Pennsylvania, was appointed an Assistant Prosecutor in the Somerset County Prosecutor’s Office in Somerville, New Jersey. Following graduation from the United States Marines Corps Officer Candidate School in 1988, he was commissioned as an officer in the U.S. Marines, attained the rank of Captain and served in Saudi Arabia during Operation Desert Shield. In 2015, Ernst & Young named Mr. O’Connor Entrepreneur of the Year® in New Jersey for his accomplishments as CEO of Advaxis. He currently serves as an advisor to the Dean of the Penn State University’s Dickinson School of Law in Carlisle, Pennsylvania.
Robert G. Petit, Ph.D.
Executive Vice President and Chief Scientific Officer
Dr. Robert Petit has 23 years of experience in all medical and scientific aspects of pharmaceutical development. He has led programs in discovery, translational development and intellectual property development and has designed and conducted U.S. and international clinical evaluation programs from Phase 1 to 4. Dr. Petit joined Advaxis from Bristol-Myers Squibb where he was the U.S. Medical Strategy Lead for the ipilimumab program, Director of Medical Strategy for New Oncology Products, and Director of Global Clinical Research. Prior to joining Bristol-Myers Squibb, Robert served as Vice President of Clinical Development at MGI Pharma and also at Aesgen Inc. His scientific focus has been to develop immunologic based therapies with a particular emphasis on immunologic oncology treatment. Robert has had significant FDA experience and has contributed to five NDA/BLA filings. Dr. Petit has a doctorate from the Ohio State University College of Medicine and a Bachelor of Science from Indiana State University.
Sara Bonstein, MBA
Executive Vice President and Chief Financial Officer
Ms. Bonstein joined Advaxis in March 2014 as the Chief Financial Officer, Senior Vice President. Ms. Bonstein has a decade of financial leadership experience in the life sciences industry with Eli Lilly & Company, ImClone Systems and Johnson & Johnson. While at Eli Lilly & Company, Ms. Bonstein was a Six Sigma Champion and Black Belt, leading multiple projects relating to clinical research, project management, finance, manufacturing and commercial sales. Prior to her Six Sigma role, Ms. Bonstein held positions of increasing responsibility at ImClone (which was acquired by Eli Lilly in 2008) including Director of Finance where she led all budget and forecast activities for preclinical, clinical and manufacturing research and development, spanning over 10 monoclonal antibody cancer therapeutics, including ERBITUX® (cetuximab), a cancer treatment with over $1.5 billion in annual sales.
Prior to joining ImClone, Ms. Bonstein was a financial analyst at Johnson & Johnson in both the Ortho McNeil Pharmaceuticals and Ortho Biotech Divisions of the company where she managed gross-to-net analysis and calculation for approximately $1.1 billion of pharmaceutical product sales. Ms. Bonstein is a 2004 graduate of Johnson & Johnson’s Financial Leadership Development Program. She holds a Bachelor of Science in Finance from The College of New Jersey and a Master of Business Administration from Rider University.
Anthony A. Lombardo
Executive Vice President and Chief Business Officer
Mr. Lombardo joined Advaxis in April 2017 as the Chief Business Officer, Senior Vice President, bringing with him nearly 30 years of leadership experience in the life sciences industry with a proven track record of helping global companies achieve significant growth.
Prior to joining Advaxis, Lombardo was a Partner as The Channel Group, where he provided strategic advisory services to biotechnology, pharma and med-tech companies. Previously, he was President and CEO of E-Z-EM Inc., where his leadership transformed the company in eight years to a value of approximately $450 million, up from a market value of approximately $10 million at the time that he joined E-Z-EM. He led the acquisition of E-Z-EM to Bracco Diagnostics for more than $241 million, where he then oversaw business operations for six years as the Chief Operating Officer. Prior to joining E-Z-EM, Lombardo served as the President of ALI Imaging Systems, Inc., which was sold to McKesson for $340 million. He has also held leadership roles at General Electric Medical Systems, Philips Medical Systems, Loral/Lockheed Martin Corp. and Sony Corporation.
Lombardo has been honored by the American College of Radiology and the Society of Abdominal Radiology for his years of service to the clinical community. He serves as Chairman of the Advisory Board of Morristown Medical Center, a part of Atlantic Health System Hospitals. He received an M.S. in Physiology from Duquesne University and a B.S. in Biology from St. Francis College.
Senior Vice President and Chief Operating Officer
Mr. Duke joined Advaxis in October 2016 as Senior Vice President and Chief Operating Officer. He brings more than 20 years of life sciences experience to the Advaxis team, and is responsible for leading operations with a focus on overseeing clinical development programs and managing early commercial planning activities. Prior to joining Advaxis, Mr. Duke was Vice President, Global Commercial Operations at Amicus Therapeutics, Inc. where he played a lead role in the build out of the international business to support the successful launch of Galafold™ (migalastat), which was granted full approval by the European Commission in 2016. Mr. Duke was one of the first employees at Amicus and held several leadership roles in program/alliance management, medical affairs and commercial planning for 10 years.
Mr. Duke also served as Executive Director, International Commercial Operations for NPS Pharma where he led several strategic business planning initiatives and helped to establish NPS International to support the ex-US commercialization of Revestive® (teduglutide) and Natpar® (rhPTH[1-84]). He received his MBA from the Wharton School, University of Pennsylvania, his MPH from the University of Medicine and Dentistry of New Jersey, and a Bachelor of Science in Chemical Engineering from Rutgers University.
Robert W. Ashworth, Ph.D.
Senior Vice President, Regulatory Affairs, Quality and Compliance
Dr. Robert Ashworth has over 30 years of pharmaceutical industry experience spanning chemistry research and regulatory affairs. During the course of his career, he has made significant contributions to the FDA approvals of 12 new drugs. His drug development and regulatory experience includes small molecules, therapeutic proteins and antibodies. He joined Advaxis from NPS Pharmaceuticals Inc., where he served as Vice President, Global Regulatory Affairs and spearheaded the global approval of drugs for rare diseases. Prior to that, he had similar roles at Otsuka Pharmaceutical Development and Commercialization, Inc. and Biovail Corporation. Earlier in his career, he held positions of increasing responsibility at Forest Laboratories Inc., BASF Pharma (Knoll) and Ciba-Geigy Corporation.
Dr. Ashworth holds a doctorate in organic chemistry from the Massachusetts Institute of Technology and a Bachelor of Science in chemistry from St. John’s University.
Thomas W. Hare
Senior Vice President, Product Development
Mr. Hare brings to Advaxis more than 28 years of experience in the biopharmaceutical and CRO industries overseeing the management of global commercial and clinical operations, data management, outsourcing and medical writing groups. As Vice President, Clinical Operations, Mr. Hare oversaw clinical operations for the company’s Lm Technology™ clinical programs.
Before joining Advaxis in May 2015, Mr. Hare served as Vice President, Drug Development Operations for Incyte Corporation. He joined Incyte in January 2003 and was responsible for the strategic growth and development of a team that planned, implemented and managed Phase 1 through Phase 3 multinational clinical trials in cancer immunotherapy and cancer inflammation.
Prior to Incyte, Mr. Hare was Director of Operations at PRA International (now PRA Health Sciences), where he was responsible for forecasting of project revenue, costs and resources, performing financial analysis to insure contract compliance, developing metrics to measure quality, and managing a team responsible for the on-time and in-budget completion of Phase 1 through Phase 3 clinical trials. Previous to PRA International, Mr. Hare served as Vice President, Clinical Operations Division for Premier Research and as Clinical Manager/Senior Clinical Scientist for Bristol-Myers Squibb. Mr. Hare received a Master of Science in exercising physiology and biomechanics from the University of Delaware.
Senior Vice President, Technical Operations
Mr. Pujols served as Executive Director, Technical Operations for Merck, Sharp & Dohme (MSD), the UK subsidiary of Merck & Co., Inc. As Executive Director, Technical Operations, Mr. Pujols led a team responsible for technical support and global supply of reliable, compliant and cost competitive biologics, vaccines and pharmaceuticals. Highlighting his success at MSD, Mr. Pujols was instrumental in spearheading partnerships with several key stakeholders and executing strategies that ensured the realization of opportunities, business continuity, innovation and financial results. Mr. Pujols also spent nine years with Merck & Co. at the beginning of his professional career.
Prior to MSD, Mr. Pujols spent seven years at MedImmune where he held positions of increasing responsibility, most recently serving as Director Clinical Manufacturing Operations, Research & Development. In this position, Mr. Pujols managed a team of development scientists and engineers responsible for scale-up, tech transfer and manufacture of pipeline biopharmaceuticals for global clinical trials. Previous to MedImmune, Mr. Pujols served as Manager, Global Technical Operations for Schering-Plough prior to its merger with Merck.
Mr. Pujols holds a Bachelor of Engineering in chemical engineering from Stevens Institute of Technology and a Master of Science in chemical engineering from Columbia University.
Vice President, Business Development
Ms. Dajani joined Advaxis in July 2016 where she is currently Vice President, Business Development. In this role, Ms. Dajani is leading Advaxis’ business development efforts, as well as corporate strategy and investor relations.
Prior to joining Advaxis, Ms. Dajani spent nearly 20 years in corporate roles at Bristol-Myers Squibb Co. (BMS). Her most recent role was as executive director for investor relations, where she led communications to the investor community around company strategy, corporate transactions, product performance, and pipeline updates. She spent several years in business development, where she was responsible for executing dozens of strategic collaborations including securing rights to key immuno-oncology products such as Yervoy (ipilimumab) and Opdivo (nivolumab). Ms. Dajani began her career at BMS in various finance roles, including valuation analyses of in-licensing, joint ventures, and mergers and acquisitions.
Ms. Dajani attended Boston University, where she earned a master’s degree in business administration with a concentration in finance and a master of arts in economics. She holds a bachelor’s degree in economics from the University of Michigan.